Indoco Remedies

Indoco Remedies EBITDA per Share

The EBITDA per Share of Indoco Remedies (INDOCO.NS) as of Oct 15, 2026 is 1.67 INR. In the previous year, EBITDA per Share was 11.47 INR — a change of -85.40% (lower).

EBITDA per Share

1.67INR

YoY

-85.40%

Last updated:

EBITDA per Share of Indoco Remedies is 2026 1.67 INR. EBITDA per Share of Indoco Remedies was 2025 11.47 INR. It decreases by -85.40% lower compared to the previous year.

The Indoco Remedies EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
8.95 INR
Jan 1, 2020
14.08 INR
Jan 1, 2021
24.65 INR
Jan 1, 2022
35.23 INR
Jan 1, 2023
29.11 INR
Jan 1, 2024
31.12 INR
Jan 1, 2025
11.47 INR
Jan 1, 2026
1.67 INR
The Indoco Remedies EBITDA per Share history
YEAREBITDA per ShareYoY
1.67INR-85.40%
11.47INR-63.15%
31.12INR+6.92%
29.11INR-17.37%
35.23INR+42.88%
24.65INR+75.15%
14.08INR+57.26%
8.95INR-37.38%
14.29INR-17.48%
17.32INR-8.97%
19.03INR+4.72%
18.17INR+38.21%
13.15INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd, listed on the National Stock Exchange of India with ticker INDOCO.NS and ISIN INE873D01024, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It employs 6,101 full-time employees and went public via an IPO on January 7, 2005. Indoco Remedies Ltd focuses on the manufacturing and marketing of formulations, including finished dosage forms and active pharmaceutical ingredients (APIs). The company serves multiple therapeutic categories such as diabetology, respiratory care, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicine. Its product portfolio includes brands like Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel. The company caters to both domestic and international markets. Indoco Remedies Ltd has subsidiaries including Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited. The company's website is https://www.indoco.com/. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

EBITDA per Share of Indoco Remedies is 1.67 INR in 2026.

EBITDA per Share of Indoco Remedies changed from 11.47 INR to 1.67 INR, representing a -85.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Indoco Remedies

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Indoco Remedies